The medical proof doesn't get much better than VMMC by Venter, Francois et al.
123
Forum
March 2012, Vol. 102, No. 3  SAMJ
The thoughtful editorial by Professor Ncayiyana concerning the 
national circumcision programme in South Africa1  rests on two 
central arguments: first, that the scientific evidence is insufficient 
to justify such ‘serious energy, money and resources’, particularly 
when circumcision programmes have the potential of diverting 
money from other more effective interventions; and second, that 
risk compensation (the potential increase in risky behaviour after 
circumcision) may nullify any benefits of circumcision.
The scientific evidence
There are few medical or public health interventions that are based 
upon evidence as strong and consistent as that for the effectiveness of 
male circumcision in preventing female-to-male transmission of HIV. 
Ncayiyana reviews the cumulative evidence from early observational 
studies, and from the three landmark randomised controlled trials 
in Africa. He notes that the studies were stopped early. However, 
they were not stopped early by investigators; individual studies 
were stopped by their independent Data and Safety Monitoring 
Board because the evidence was strong enough to deem unethical 
the withholding of circumcision from the control group. All men 
were then offered circumcision and, as Ncayiyana points out, an 
opportunity for direct long-term follow-up was lost. However, not 
all was lost. Observational research continues to strengthen the 
experimental findings. For example, a community-based survey of 
the Orange Farm community was recently presented, which showed 
an increase in circumcision coverage from 15.6% in 2007 to 49.4% 
in 2010, with a concomitant HIV seroprevalence of 20% among 
uncircumcised men and 6.2% among circumcised men, and no 
correlation between circumcision status and sexual behaviour.2
Risk compensation – does it exist?
Ncayiyana argues that circumcision may increase risk compensation 
and therefore increase HIV transmission. The Orange Farm trial did 
indeed find a slight increase in risky behaviour in the circumcised 
men, but, in spite of this, there was a still 60% reduction in HIV 
transmission.3 On the other hand, the Uganda trial  ‘did not find 
evidence that men in the intervention group adopted higher sexual 
risk behaviours  than those in the control group. This could have 
been due to the intensive health education provided during the trial 
to minimise risk compensation.’4
The Kenyan trial found that ‘the differences (of risk behaviour) 
between the two groups are attributable to increases in safer sexual 
practices in the control group rather than to riskier behaviour 
patterns in the circumcision group, indicating that risk compensation 
did not occur during the 24 months of this study’.5 In fact, condom 
use went up in both groups and unprotected sex went down in both. 
This is probably a function of intensive counselling. Further studies 
in the Kenyan cohort and community show that risk compensation is 
not a necessary consequence and that circumcision can be used as an 
opportunity to educate men about HIV prevention.6-8
Most importantly in relation to South Africa, Ncayiyana cites a 
survey by Bridges et al. claiming that this study links demand for 
circumcision with the idea that a circumcised man no longer needs to 
use a condom.9 But the results of this study are: ‘Johannesburg, South 
Africa, shows that demand for circumcision is largely determined 
by the perceived benefits of reduced HIV/STI transmission risk, 
better hygiene and better sex … [O]ur analysis shows that – in 
the aggregate – condom avoidance is not perceived as a benefit of 
circumcision. Our findings suggest that moral hazard concerns 
related to risk compensation via condom avoidance associated with 
male circumcision are exaggerated.’9
Cost and impact of circumcision
Finally, Ncayiyana compares the HIV epidemic in South Africa with 
Australia and the USA, stating that Australia does not recommend 
universal circumcision, and that it therefore is not right for South 
Africa. There are very different drivers for the HIV epidemic in 
South Africa versus Australia, and comparing them is unwise. In 
Australia, for example, 100 cases of heterosexually transmitted HIV 
are diagnosed annually.10 On the other hand, in South Africa about 
1 400 new HIV infections occur per day, almost all via heterosexual 
transmission.11 And despite the relatively high rate of heterosexual 
transmission (31%) in the USA, the seroprevalence rate is 0.4% and 
the major route of transmission is men who have sex with men,12 
which is certainly not the case in South Africa. 
The high heterosexual transmission rate in South Africa means that 
the number of men who must be circumcised to prevent one HIV 
infection is much lower than in the USA or Australia. UNAIDS and 
the World Health Organization (WHO), using South African data and 
heterosexual transmission models, estimate that one new HIV infection 
can be avoided for every 5 to 15 circumcisions.13 And this estimate takes 
into account possible risk compensation across the entire population.
Large-scale circumcision will consume resources, energy and 
time, but, as Hillary Clinton said, ‘we all must step up our use of 
combination prevention’.14 Because the impact of circumcision is 
so much greater in South Africa, scaling up circumcision is much 
more cost-effective compared with other countries. The cost savings 
in HIV prevention in high-prevalence areas is estimated at between 
US$150 and nearly $900 per infection prevented over a 10-year time 
horizon.13 If 1 000 adult males were circumcised in South Africa’s 
Gauteng province alone, $2.4 million could potentially be saved 
in HIV treatments over 20 years.15 The money saved on treatment 
could be reinvested in testing, treatment, and prevention of vertical 
transmission – other methods of prevention that Ncayiyana points 
out have a proven impact.
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The editorial1 on voluntary medical male circumcision (VMMC) has 
many scientific inaccuracies and ignores the latest literature. Previous 
‘scientific’ challenges on the VMMC evidence have had rebuttals 
co-signed by many local prevention scientists.2,3 Ncayiyana does not 
acknowledge that despite the long presence of the prevention ‘abstain, 
be faithful and condomise’ (ABCs), the impact on HIV prevention 
progress has been slow, resulting in hundreds of thousands of 
mostly young South Africans dying. Substantially lowering incidence 
will only be achieved with the introduction and scale-up of new 
technologies. 
To argue that VMMC has not been ‘field tested’ is inaccurate. 
The editorial’s opening sentence quotes the ‘real world’ evidence. 
In Orange Farm, where many men were circumcised, a study 
demonstrated a 76% decrease in new HIV infections among those 
circumcised. Uganda reported a similar post-trial result (73%).4 This 
builds on the observational evidence quoted in the editorial. It is 
unclear why neonatal VMMC is ‘proscribed’ in South Africa, as the 
editorial and many anti-VMMC groups claim; it occurs for cultural, 
religious and health reasons, and there is no law barring it. To ask 
for long-term evidence of the efficacy for HIV prevention of VMMC 
in neonates will take over 20 years to measure. It is biologically 
implausible that it would not have the same effect as in adults, 
and not implementing it would mean we do not protect the next 
generation of young men from a life-threatening illness. No similar 
evidence is requested for interventions such as hepatitis B or human 
papillomavirus vaccines.
Independent safety boards terminated the three VMMC efficacy 
studies, and not the researchers. Not to offer a proven (around 
60% protective) intervention to the control group on stopping the 
studies violates clinical research ethics. Ncayiyana selectively quoted 
a statement by the Australian Federation of AIDS Organisations 
that ‘correct and consistent condom use, not circumcision, is the 
most effective means of reducing female-to-male transmission, 
and vice-versa’. But there is no published evidence comparing the 
two interventions. Additionally, the organisation’s (2007) statement 
later states that the epidemiology of HIV transmission completely 
differs between Australia and Africa, and its website stated in 2011 
‘Circumcision significantly reduces the rate of HIV acquisition (50 
- 70%) in men with HIV-positive female partners.’5 The ‘scathing 
critique’ of the MMC data by Van Howe and Storms referred to by 
Ncayiyana makes very little sense. They claim that ‘Conservatively 
for the three trials, 89 of the 205 infections (43.1%) were sexually 
transmitted.’ How were the other infections acquired? The choices 
would seem to be injection drug use or contact with blood and 
blood products. The evidence for the predominantly heterosexual 
transmission of HIV in sub-Saharan Africa is overwhelming. 
Furthermore, if the infections were not sexually transmitted, how 
would the condom use data discrepancy argued in the editorial as 
a weakness of the three studies then prevent them? The discussion 
on the various differential rates regarding VMMC and observed 
HIV prevalence in different South African communities relies 
on circumcision self-reports, which are unreliable when assessing 
culturally performed circumcision, in which the amount of foreskin 
removed varies. These observational studies are rendered irrelevant 
by good randomised control trial and follow-up community evidence. 
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We found no reference to the assertion that black Americans have 
the highest rates of circumcision among American men, rather 
the opposite.6 The argument that VMMC does not protect women 
from HIV is peculiar. Reducing the pool of HIV among men, in 
a predominantly heterosexual epidemic, will mean fewer men 
with HIV, who will expose fewer women. It also appears to reduce 
circulating HPV, and therefore likely to reduce cervical cancer rates,7 
as demonstrated in other communities where MMC is the norm. 
The risk disinhibition data from properly conducted studies does not 
suggest any additional risk taking.8,9
South Africa has some of the world’s top HIV prevention scientists, 
and almost all of the biomedical breakthroughs in the field have 
either occurred in South Africa or included South Africans, including 
VMMC. The call for VMMC implementation came from South 
Africans after the Orange Farm study results were announced, was 
considered by the Department of Health (DoH), and was discussed 
extensively by all 19 sectors within the South African National AIDS 
Council (SANAC). The VMMC consensus involved prominent 
South Africans beyond the health sector, including Deputy President 
Motlanthe, who chairs the SANAC. Only after careful consideration 
of the science and the social and cultural issues around VMMC did 
the DoH and the SANAC decide to include VMMC in the 2012 - 
2016 National Strategic Plan. This intervention is regarded as a game 
changer in South Africa’s HIV prevention efforts and all provinces 
are prioritising efforts to accelerate access. The DOH has committed 
large budgets to VMMC rollout, and contrary to the editorial, is not 
kowtowing to donor agency agendas for support. Funding for VMMC 
from donors was requested from the South African government and 
granted, much like other support to ART and vaccine rollout. This 
national decision aligns with international recommendations from 
the WHO and UNAIDS.
No one argues that any one HIV prevention intervention 
will work alone, or that VMMC is 100% protective. Drivers of 
the HIV epidemic are complex and there is no ‘one size fits all’ 
prevention. However, the ABCs have proved insufficient in South 
Africa or elsewhere, in terms of reversing the HIV epidemic 
or addressing the complex drivers of HIV transmission. We 
need additional interventions to make an impact, using the 
combination prevention approach now adopted internationally 
and locally. Modelling studies strongly suggest increasingly 
striking implications of scaling-up of VMMC in averting 
millions of infections and deaths and saving billions of rands in 
the long run. Further delay will be a major failure to capitalise 
on scientific evidence to save lives and improve the quality of 
life of our population. Circumcision has an evidence base for 
efficacy, especially for protecting men, rivalling the best proved 
interventions in medicine. Its implementation will be complex, 
challenging and costly, but it works, and is needed as part of our 
prevention toolbox.
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Voluntary male medical circumcision –  
Dan Ncayiyana responds
I thank the above authors, all acknowledged HIV/AIDS experts, for 
their robust responses. South Africa and the SA HIV/AIDS research 
community have indeed been at the forefront of the global effort to 
better understand and to contain the HIV/AIDS epidemic, and there 
is no gainsaying the motive of the VMMA proponents to control 
and ultimately to eradicate the disease. That said, the envisaged mass 
roll-out of a surgically invasive prophylactic intervention is without 
historical parallel, and it is only appropriate that the VMMC project 
is deliberated within the medical profession beyond the immediate 
circles of the panels and committees driving the initiative.
The significance of the evidence from the three African randomised 
controlled trials (RCTs) is not at issue. However, this evidence seems 
to have acquired considerable interpretation creep along the way, 
with inferences of ‘lifelong protection’, and of benefits of neonatal 
circumcision that are not self-evident from the RCTs. Clark et al. 
boldly assert in respect of sub-Saharan Africa that ‘Mandating 
[my emphasis] neonatal male circumcision is an effective therapy 
that has minimal risks, is cost efficient and will save human lives. 
Neonatal male circumcision is medically necessary and ethically 
imperative’.1 There is no good evidence to back this up. Based on 
their interpretation of the Children’s Act 38 of 2005, paediatric 
surgeon and ethicist Sidler and colleagues2 hold the view that ‘infant 
non-therapeutic circumcision in South Africa (is) illegal, making the 
discussion of forced infant circumcision moot’.
The debate is about what the evidence means and what its 
role should be in the greater HIV prevention strategy. UCT’s 
Myers and Myers have cautioned that ‘given the epidemiological 
uncertainties, and the cultural, ethical and logistical barriers, it seems 
neither justified nor practicable to roll out male circumcision as a 
mass anti-HIV/AIDS intervention’.3 Pointing to the long history of 
circumcision as an intervention in search of a malady, they remind 
us that ‘Superficially convincing justifications for this surgery have 
abounded since the mid-19th century’4 to prevent masturbation, 
insanity, idiocy, epilepsy, TB, STIs, cervical cancer, and penile cancer. 
Certainly, circumcision should be readily accessible to individuals 
who, forearmed with full information on the potential benefits, the 
caveats and the unknowns, make a personal choice to be circumcised. 
To argue that ‘despite the long presence of the ABCs, HIV 
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prevention has been slow’ is not fair comment. It is counterintuitive 
to believe that VMMC will fare any better, or that men will be any 
more amenable to having their foreskin excised than they are to 
wearing a condom. On the contrary, VMMC is likely to meet with 
ever-increasing resistance, not least because of deeply rooted cultural 
attitudes,5 much as this dimension has tended to be underplayed in 
the VMMC euphoria. More importantly, it is worth recalling that 
until fairly recently, the ABC message has struggled to be heard in 
the face of AIDS denialism, with the TAC fighting running battles 
with the political establishment, doctors in the public service getting 
punished for promoting orthodox HIV practices, and Dr Matthias 
Rath peddling miracle AIDS cures under the protection of top 
government officials. That the HIV incidence has shown signs of 
abatement at all is evidence of the staying power of the ABC strategy. 
My concern about offshore funding (and much of the advocacy) 
driving VMMC is not off the wall. Venter was quoted in the NEJM 6 
as expressing similar sentiments that ‘Currently all of the funding is 
coming from Western nations … and this makes people suspicious.’ 
This remains the case in most southern African countries beyond 
our borders. I remain sceptical that VMMC has been sufficiently 
field-tested to validate a mass VMMC campaign, or that the goal to 
circumcise millions of men in our region in 5 years is even achievable. 
Without detracting from the imperative to pursue a multi-pronged 
prevention strategy, I believe that the proven, simpler and more 
affordable approaches of the ABCs, VCT and ARTs should remain 
the primary prevention strategy in our region.
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